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Abstract
Background: Prostate biopsy guided by computer-assisted fusion of magnetic resonance imaging
(MRI) andtransrectalultrasound (TRUS) images (MRIgroup)hasnotyetbeencomparedwith12-core
random biopsy (RB; control group) in a randomized controlled trial (RCT).
Objective: To compare the rate of detection of clinically signiﬁcant prostate cancer (csPCa)
between the two groups.
Design, setting, and participants: This RCT included 175 biopsy-naı¨ve patients with suspicion for
prostate cancer, randomized to an MRI group (n = 86) and a control group (n = 89) between
September 2011 and June 2013.
Intervention: In the MRI group, two-core targeted biopsy (TB) guided by computer-assisted
fusion of MRI/TRUS images of MRI-suspicious lesions was followed by 12-core RB. In the control
group, both two-core TB for abnormal digital rectal examination (DRE) and/or TRUS-suspicious
lesions and 12-core RB were performed. In patients with normal MRI or DRE/TRUS, only 12-core
RB was performed.
Outcomes measurements and statistical analysis: The detection rates for any cancer and csPCa
were compared between the two groups and between TB and RB.
Results and limitations: Detection rates for any cancer (MRI group 51/86, 59%; control group
48/89, 54%; p = 0.4) and csPCa (38/86, 44% vs 44/89, 49%; p = 0.5) did not signiﬁcantly differ
between the groups. Detection of csPCa was comparable between two-coreMRI/TRUS-TB (33/86,
38%) and 12-core RB in the control group (44/89, 49%; p = 0.2). In a subset analysis of patients
with normal DRE, csPCa detection was similar between two-core MRI/TRUS-TB (14/66, 21%) and
12-core RB in the control group (15/60, 25%; p = 0.7). Among biopsy-proven csPCas in MRI group,
87% (33/38) were detected by MRI/TRUS-TB. The deﬁnition of csPCa was only based on biopsy
outcomes.
Conclusion: Overall csPCa detection was similar between the MRI and control groups. Two-core
MRI/TRUS-TB was comparable to 12-core RB for csPCa detection.
Patient summary: Our randomized controlled trial revealed a similar rate of prostate cancer
detection between targeted biopsy guided by magnetic resonance imaging (MRI) and transrectal
ultrasound (TRUS) and 12-core random biopsy. The traditional 12-core random biopsy may be
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Prostate biopsy is essential for diagnosis, risk stratification,
and treatment planning in prostate cancer (PCa). The
guidelines of the European and American Urological
Associations recommend a 10–12-core systematic trans-
rectal ultrasound (TRUS)-guided prostate biopsy as the gold
standard for primary diagnosis, including a targeted biopsy
(TB) from suspect areas detected on digital rectal examina-
tion (DRE) or TRUS [1,2]. Because of its recognized sampling
error, 12-core random biopsy (RB) may be unreliable for
accurate detection and characterization of clinically signif-
icant PCa (csPCa) [3].
There is growing evidence that MRI can reliably identify
csPCa. An increasing number of studies have demonstrated
that computer-assisted MRI/TRUS image-fusion TB is an
effective and accurate method for csPCa diagnosis [4]. Nev-
ertheless, most previous trials included heterogeneous and
highly selected patient populations, which represent signifi-
cantbias in interpretationof the results.WhetherMRI should
be used before a primary biopsy remains a matter of debate.
To the best of our knowledge, no randomized controlled
trials (RCTs) comparing the outcomes of computer-assisted
MRI/TRUS-TB with traditional 12-core systematic RB for
primary diagnostic biopsy have been published. We
[(Fig._1)TD$FIG]Fig. 1 – Study floundertook a prospective RCT to assess and compare the
outcomes of these two biopsy methods.
2. Patients and methods
AﬂowdiagramforthestudyisshowninFig.1.BetweenSeptember2011and
June 2013, all 183 eligible patients scheduled for a primary prostate biopsy
atourdepartmentwererandomlyallocatedata ratioof1:1 toMRI/TRUS-TB
for MR-suspicious lesions combined with 12-core systematic RB (MRI
group)or12-coreRBcombinedwithTBforpalpableand/orTRUS-suspicious
lesions (control group). Overall, 175 patients (96%) were analyzed (Fig. 1).
The inclusion criteria were: (1) age <75 yr, (2) veriﬁed prostate-speciﬁc
antigen (PSA) increase to4–20ng/ml and/or abnormalDRE; (3) noprevious
prostate biopsy; and (4) signed informed consent. The exclusion criteria
were: (1) previous prostate biopsy orMRI of the prostate; (2) contraindica-
tiontoMRI;and (3)nosigned informedconsent.Noneofpatients in thisRCT
have previously been included in published cohorts.
2.1. Study characteristics and endpoints
This prospective, single-institution RCT compared outcomes between
the two groups. The study was approved by the local regional committee
for medical and health ethics and the study was registered on
ClinicalTrial.gov (NCT01455792). Oslo University Hospital alone sup-
ported the trial.
The primary endpoint was cancer detection rate (CDR) for any cancer
and csPCa in the MRI and control groups. The secondary endpointsw diagram.
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12-cores-RB, [3_TD$DIFF](2) Gleason score, maximum cancer core length and cancer
involvement in comparison between the TB vs RB, [4_TD$DIFF](3) correlation between
Gleasonscoreonbiopsy andradical prostatectomy(RP)whenconceivable.
2.2. Randomization
Permuted block randomization with an undisclosed variable was used.
The Department of Biostatistics at Oslo University Hospital generated
randomized, sequentially numbered, opaque sealed envelopes. A research
nurseopenedenvelopes consecutively after eachpatient registered for the
trial and the patient was then assigned to either the MRI group or the
control group.
2.3. Imaging and analysis
Prebiopsy MRI was performed in all patients randomized to the MRI
group using a 1.5-T Avanto scanner (Siemens, Erlangen) without an
endorectal coil. A detailed description of MRI acquisition and the post
processing of images has been reported. [5]. All MR-images were
interpreted by one radiologist (E.R.) with experience of greater than
1000MRI-prostate at the start of this study. The level of cancer suspicion
for MRI-detected lesions was graded as highly suspicious, likely, or
equivocal based on signal quality on T2w and signal intensity on
T2-corrected b1000, apparent diffusion coefﬁcient, and b2000 images
[5]. These levels correspond to the highest three of the ﬁve levels of
Prostate Imaging Reporting and Data System (PIRADS) [6].
2.4. Prostate biopsy
All biopsies were performed in the outpatient clinic with oral antibiotic
prophylaxisandperiprostaticblockanesthesiaaccording toEAUguidelines.
2.4.1. MRI group
All biopsies in theMRI groupwere performed by one urologist (E.B.) with
experience of more than 200 MRI TBs at the start of the study. The
median time lag between MRI and biopsy was 7 d (interquartile range
2–10 d). An Accuvix-V10 ultrasound machine with an end-ﬁring three-
dimensional transrectal transducer (Medison, Seoul, Korea) and a
computer-assisted elastic image fusion system with real-time 3D
tracking technology (UroStation; Koelis, Grenoble, France) were used
for all patients [5,7–10].
Two-core MRI/TRUS-TB was performed on lesions with a PIRADS
score of 3–5 on MRI (median 2 cores, range 1–4 cores per patient). This
was followed by 12-core RB. In cases with negativeMRI ﬁndings (PIRADS
score of 1–2), only 12-core RB was performed.
2.4.2. Control group
Two dedicated senior urologists (L.M.E. and G.M.) with more than 20 yr
of experience performed all TRUS biopsies. If a palpable and/or TRUS
suspicious lesion was found, two targeted biopsy from the lesion were
performed, followed by 12-core RB using a BK-Medical model
1846 ultrasound unit and a biplanar 5–10-MHz side-ﬁring transducer
(model 8531; BK-Medical, Herlev, Denmark).
2.5. Histology
Biopsy cores were labeled individually and the Gleason score, maximum
cancer core length (MCCL), and cancer core involvement were recorded
for each one. The same team of uropathologists performed histopatho-
logic analyses of all cores and RP specimens [11]. Pathologists were not
blinded to assignment to study groups. csPCa on biopsy was deﬁned as
MCCL 5 mm for Gleason 6 disease or any MCCL for Gleason 7 disease
according to standards of reporting for MRI-targeted biopsy studies(START) criteria [12]. Clinically insigniﬁcant cancer was deﬁned as MCCL
<5 mm for Gleason 6 cancer. csPCa on step-sectional analysis of RP was
deﬁned as cancer volume 0.5 ml for Gleason 6 disease or any cancer
volume for Gleason 7 [13]. If the Gleason scores for biopsy and RP
specimens were the same, the results were categorized as concordant.
Gleason 7 tumors were discriminated as 3 + 4 and 4 + 3.
2.6. Statistical analyses
Differences in cancer detection rates between the MRI and control
groups were compared using the Pearson x2 test or Fisher’s exact as
appropriate. An independent-sample t-test and the Mann-Whitney
U-test were used to assess differences in means for quantitative variables
after testing the distribution for normality. Concordance between TB and
RPspecimens forGleason scorewasevaluatedusing thekappa (k) statistic.
Data were analyzed using SPSS v.22.0 (IBM Corp., Armonk, NY, USA).
Statistical signiﬁcance was considered achieved if p < 0.05.
2.7. Sample size estimation
A retrospective data review for 12-core TRUS primary biopsies
performed at our institution during 2009 revealed a cancer detection
rate of 35%, in agreement with published trials [14]. At the start of the
present study, there were no publications on cancer detection rates in
biopsy-naı¨ve men undergoing MRI/TRUS-TB. On the basis of preliminary
results for ourMRI/TRUS-TB technique before the study [5], we expected
a cancer detection rate of approximately 55–60%. We therefore
estimated that we would achieve a 20–25% difference in detection rate
between the two groups. At a signiﬁcance level of 0.05, 124–192 patients
(64–96 in each group) would be required to provide 80% power with a
two-tailed test for two independent proportions.
3. Results
Data were available for 175 patients randomized to the MRI
group (n = 86) or the control group (n = 89; Fig. 1). There
were no differences in age, PSA, prostate volume, or clinical
stage between the groups (Table 1). A total of 66 (77%) men
in the MRI group and 60 (67%) in the control group had
normal DRE.
3.1. Overall cancer detection rates in the entire cohort
There was no significant difference between the MRI and
control groups in the overall detection rate of any cancer
(59% vs 54%, p = 0.4) or detection of csPCa (44% vs 49%,
p = 0.5; Table 2). Detection of csPCa was comparable
between two-core MRI/TRUS-TB (38%) and 12-core RB in
the control group (49%; p = 0.2).
3.2. csPCa detection in patients with normal DRE
In patients with normal DRE, csPCa detection was similar
between two-core MRI/TRUS-TB in the MRI group (14/66,
21%) and 12-core RB in the control group (15/60, 25%;
p = 0.7).
3.3. MRI/TRUS-TB detection rate according to PIRADS score
Table 3 presents rates of csPCa detection by two-core MRI/
TRUS-TB according to PIRADS score. MRI/TRUS-TB detected
Table 1 – Demographic characteristics of the study participants
Overall MRI group TRUS group p value
Patients before prostate biopsy (n) 175 86 89
Age (yr) 65 (59–69) 64 (58–69) 65 (59–69) 0.5
Prostate-speciﬁc antigen (ng/ml) 7.3 (5.5–9.9) 6.9 (5.2–9.2) 7.6 (5.9–10.4) 0.1
Prostate volume (ml) a 42 (30–59) 45 (33–60) 40 (29–52) 0.053
Abnormal DRE, n (%) 49 (28) 20 (23.2) 29 (32.6) 0.1
Patients with normal DRE (n) 126 66 60
Age (yr) 63 (58–68) 62 (58–67) 64 (58–68) 0.6
Prostate-speciﬁc antigen (ng/ml) 6.5 (5.1–8.9) 6.3 (4.9–8.6) 6.6 (5.2–9.9) 0.2
Prostate volume (ml) a 45 (33–60) 52 (34–63) 43 (31–59) 0.2
Patients with pathologic DRE (n) 49 20 29
Age (yr) 68 (63–72) 68 (65–71) 67 (63–72) 0.9
Prostate-speciﬁc antigen (ng/ml) 8.7 (6.7–13) 8.8 (5.8–13.6) 8.6 (7.2–12.3) 1
Prostate volume (ml) a 35 (25–52) 35 (25–53) 35 (25–52) 0.8
MRI = magnetic resonance imaging; TRUS = transrectal ultrasound; DRE = digital rectal examination.
Data for continuous variables are presented as median (interquartile range).
a As measured using TRUS.
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97% of the 29 MRI-detected lesions with a PIRADS score of
4–5.
3.4. Cancers missed on MRI, TB, and RB
3.4.1. MRI group
In the MRI group, seven tumors (7/51; 14%) were not
detected onMRI and three tumors (6%) were missed on TB.
A total of five missed cancers (5/51; 10%) were csPCa
(Table 4, Fig. 2). RB missed three cancers (two Gleason
7 and one Gleason 6), all of which were detected by TB
(Fig. 3).Table 2 – Comparison of overall cancer detection rates for the
whole cohort and for patients with normal DRE
MRI
group
Control
group
p value
Total cohort
Group size (n) 86 89
Overall detection of any
cancer, n (%)
51 (59) 48 (54) 0.4
Overall detection of csPCa, n (%) 38 (44) 44 (49) 0.5
csPCa detected by RB, n (%) 31 (36) 44 (49) 0.09
csPCa detected by TB
(MRI-TB vs DRE/TRUS-TB), n (%)
33 (38) 16 (18) 0.002
csPCa detected by MRI-TB vs RB
in control group, n (%)
33 (38) 44 (49) 0.2
Patients with normal DRE
Group size (n) 66 60
Overall detection of any
cancer, n (%)
31 (47) 18 (30) 0.07
Overall detection of CsPca, n (%) 19 (29) 15 (25) 0.7
csPCa detected by RB, n (%) 16 (24) 15 (25) 1
csPCa detected by TB
(MRI-TB vs TRUS-TB), n (%)
14 (21) 0 (0) 0
csPCa detected by MRI-TB vs
RB in control group, n (%)
14 (21) 15 (25) 0.7
csPCa = clinically signiﬁcant cancer, deﬁned as maximum cancer core
length (MCCL) 5 mm for Gleason 6 or any MCCL for Gleason 7 disease;
DRE = digital rectal examination; MRI = magnetic resonance imaging;
RB = random biopsy; TB = targeted biopsy; TRUS = transrectal ultrasound.3.4.2. Control group
In the control group, none of 16 tumors diagnosed by RB
was identified on TRUS. Three cancers were Gleason 6, ten
were Gleason 7, twowere Gleason 8, and onewas Gleason 9.
3.5. Gleason score agreement
Gleason score agreement between biopsy and prostatec-
tomy specimens for csPCa was 73% (k = 0.56) in the MRI
group and 60% (k = 0.45) in the control group (p = 0.9).
3.6. Histopathologic characteristics on RB and TB
Histopathologic characteristics in terms ofMCCL and cancer
core invasion on RB and TB were comparable between the
MRI and control groups (Table 5).
4. Discussion
To the best of our knowledge, this is the first RCT to compare
cancer detection rates between computer-assisted image-
fusion MRI/TRUS-TB and 12-core systematic RB in biopsy-
naı¨ve men. Comparison revealed no significant differences
in overall detection rates for any cancer or for csPCa
between the MRI and control groups.
Importantly, our results demonstrate that two-coreMRI/
TRUS-TB has a comparable detection rate to 12-core RB
(p = 0.2) for csPCa. This finding was further supported by
similar detection rates (21% vs 25%, p = 0.7) in the subset of
patients with normal DRE. It is conceivable that in the entire
cohort, positive DRE results allowed precise sampling from
nodular csPCa, while in the subset of patients with normal
DRE, MRI/TRUS-TB only allowed reliable sampling from
MRI-visible csPCas that were nonpalpable or difficult to see
on TRUS.
MRI can play a role in visualizing csPCa. Among biopsy-
proven csPCas in the MRI group, 87% were detected byMRI/
TRUS-TB. Of 29MRI-detected lesions with a PIRADS score of
4–5, 97% (28/29) were revealed as csPCa by MRI/TRUS-TB.
Taken together, our results indicate that two-core
Table 3 – Detection of clinically significant prostate cancer (csPCa) by targeted biopsy (TB) and systematic random biopsy (RB) for 86 patients
in the magnetic resonance imaging (MRI) group
Total cohort PIRADS 1/2 PIRADS 3 PIRADS 4/5
Patients, n (%) 86 (100) 23/86 (27) 21/86 (24) 42/86 (49)
csPCa overall detection, n (%) 38/86 (44) 3/23 (13) 6/21 (29) 29/42 (69)
csPCa detected by MRI/TRUS-TB, n (%) 33/38 (87) – 5/21 (25) 28/29 (97)
csPCa detected by systematic RB alone
Missed by MRI, n (%) 4/38 (11) 4/4 (100) 0 (0) 0 (0)
Missed by TB, n (%) 2/38 (5) – 1/21 (4) 1/29 (3)
MRI/TRUS-TB = MRI and transrectal ultrasound fused TB; PIRADS = prostate imaging and reporting data system; – = not relevant.
The median (interquartile range) MRI-estimated tumor volume was 0.5 (0.4–1.0) ml for biopsy-negative tumors and 1.1 (0.5–2.1) ml for biopsy-positive tumors
(p = 0.011)/
Table 4 – Overview of patients in whom magnetic resonance imaging (MRI) and targeted biopsy (TB) failed to detect clinically significant
prostate cancer (csPCa)
Patient Age
(yrs)
PSA
(ng/ml)
PV
(ml)
MTV
(ml)
TLN
on MRI
(segment) b
Positive
RBs (n)
Gleason
score SB
RB MCCL
(mm)
csPCa Positive RB
location
(segment) b
Treatment HTV
(ml)
Gleason
score RP
specimen
TLN
on RP
specimen
1 61 7.3 52 – a – 2 5 + 4 4 Yes 1p, 2p RP 2 5 + 4 1p, 2p
2 62 9.9 55 – a – 1 3 + 4 2 Yes 10p RP 0.1 3 + 3 10p
3 67 6 155 – a – 2 3 + 4 6 Yes 1p, 2p Focal HIFU – – –
4 57 5.9 29 – a – 1 3 + 3 5 Yes 9p AS – – –
5 66 8.7 34 – a – 3 3 + 3 6 Yes 5p, 11p AS – – –
6 60 4.3 75 3.5 3p 1 3 + 3 1 No 3p AS – – –
7 64 6.6 80 – a – 1 3 + 3 1 No 8p AS – – –
8 50 5.6 60 0.2 11p 1 3 + 3 2 No 11p AS – – –
9 69 5.1 43 – a – 1 3 + 3 3 No 12p AS – – –
10 53 8.4 45 0.6 4p 2 3 + 3 4 No 10p AS – – –
PSA = prostate speciﬁc antigen; PV = prostate volume; MTV = MRI tumor volume; TLN = tumor location; RB = random biopsy; SB = systematic biopsy;
MCCL = maximum cancer core length; HTV = histologic tumor volume; RP = radical prostatectomy; AS = active surveillance; HIFU = high-intensity focused
ultrasound.
a No tumor detected on MRI.
b Segment location according to a schema comprising 27 regions of interest [13].
[(Fig._2)TD$FIG]
Fig. 2 – Results for a 59-yr-old man with prostate-specific antigen of 7.6 ng/ml, a normal digital rectal examination, and a prostate volume of 50 ml.
The patient had a positive family history of metastatic prostate cancer (his father). Prebiopsy magnetic resonance imaging, in terms of
(A) a T2-weighed image, (B) a T2-weighted image with superimposed b2000, and (C) an apparent diffusion coefficient map with color overlay, was
normal. (D,E) A 12-core random biopsy revealed Gleason 4 + 5 and 5 + 4 prostate cancer in the paramedial left prostate base and mid gland
(demonstrated in three-dimensional registered biopsy needle trajectories; UroStation). Positive cores are registered as red bars; the cancer core length
was 4 and 3 mm (50% and 37% cancer core invasion). Green bars represent negative cores. The patient was treated with radical prostatectomy.
(F) Histologic analysis of a step-sectioned prostate specimen confirmed pT3 Gleason 5 + 4 prostate cancer with neuroendocrine differentiation
localized in the central and peripheral zone. The tumor dimensions were 27 mm T 16 mm T 16 mm (3.5 ml) and the tumor location corresponded to
the three-dimensional location of positive cores.
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Fig. 3 – Results for a 67-yr-old man with prostate-specific antigen of 7.2 ng/ml, a normal digital rectal examination, and a prostate volume of 75 ml.
Prebiopsy magnetic resonance imaging (MRI) suggested anterior prostate cancer visible on (A) axial T2-weighted images and (B) an apparent diffusion
coefficient map with color overlay (arrows). MRI/transrectal ultrasound (TRUS)-targeted biopsy (red bars), as demonstrated by (C) axial and (D) sagittal
MRI/TRUS fused images, revealed Gleason 3 + 4 prostate cancer. The cancer core length was 9 and 5 mm (53% and 45% cancer core invasion). The
patient was treated with radical prostatectomy. (E) A step-sectioned prostate specimen confirmed pT2 Gleason 3 + 4 prostate cancer. The tumor
dimensions were 20 mm T 17 mm T 12 mm (2.2 ml) in the right anterior mid-gland region. (F) Positive biopsies (red bars) and the targeted region
(yellow circle) shown in (C) and (D) corresponded to the three-dimensional tumor location in segment 10p.
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csPCa, and was more effective for MRI-detected cancers
with a PIRADS score of 4–5. Thus, 12-core RB may be
replaced by two-core MRI/TRUS-TB, especially for MRI-
detected disease with PIRADS scores of 4 and 5.
A few prospective studies have evaluated the superiority
of the use of MRI data for prostate biopsy in comparison
with conventional RB [15–18]. However, to the best of our
knowledge, our study is the first RCT to compare computer-
assisted MRI/TRUS image-fusion biopsy with conventional
12-core RB. Siddiqui et al [15] reported that in a prospective
single-arm cohort of 1003 men, MR/TRUS computer-
assisted image-fusion biopsy led to increased detection of
high-risk cancer and reduced detection of low-risk cancer
[15]. In an RCT of 1140 patients, Panebianco et al [16] found
that a TRUS-guided biopsy technique using prebiopsy MRITable 5 – Histopathologic characteristics on random biopsy (RB)
and targeted biopsy (TB) by digital rectal examination (DRE) status
in 49 patients with pathological DRE
MRI group Control group p value
Normal DRE
Patients (n) 66 60
RB total CCL (mm) 178  23 184  32 0.6
RB maximum CCL (mm) 5.1  2.6 5.7  3.6 0.5
RB maximum CCI (%) 47  23 48  27 0.9
Pathologic DRE
Patients (n) 20 29
RB total CCL (mm) 167  29 184  28 0.043
RB maximum CCL 7.9  3.2 8.9  4.1 0.2
RB maximum CCI (%) 68  24 64  26 0.9
TB total CCL (mm) 26.4  6.4 25.8  5.5 0.8
TB maximum CCL (mm) 10.9  3.1 9.4  3.4 0.2
TB maximum CCI (%) 77  16 68  26 0.2
CCL = cancer core length; CCI = cancer core invasion.
Data for continuous variables are presented as mean  standard deviation.(with careful targeting of the sextant part estimated to
contain an MRI-suspicious lesion using TRUS guidance
alone) without MRI/TRUS image-fusion technology was
superior to conventional RB [16]. In a prospective single-
arm study, Pokorny et al [17] compared in-bore TB to TRUS-
guided RB and TB of lesions visible on TRUS without any
image fusion system. Quentin et al [18] compared in-bore
MRI-guided biopsy to RB in a prospective single-arm study.
As reported by Siddiqui et al [15], multiparametric MRI
may have a role in identifying just csPCa without
overdiagnosis of clinically insignificant cancer. The role of
prostate biopsy is progressively changing over time
[19]. The significance of prostate biopsy has evolved from
pure detection of any cancer to better characterization of
clinically important cancer to assist in clinical management
of patients [19]. Appropriate biopsy mapping with accurate
characterization and three-dimensional localization of
csPCa is now the cornerstone of diagnosis for tissue
preservation strategies such as active surveillance and
focal therapy. Detection and subsequent treatment of
clinically insignificant cancer do not improve life expectan-
cy [20] but expose patients to an unnecessary risk of side
effects and incur health care costs. Therefore, clinically
insignificant cancer might not have to be identified.
Emerging MRI technology could potentially improve
csPCa detection through better visualization and character-
ization of lesions and guidance of precise TB. A higher
prevalence of image-targeted biopsy-proven cancers in
suspicious areas has been reported [21–24], which can
result in better csPCa characterization via precise localiza-
tion, prediction of Gleason grade, and more accurate cancer
core length [10].
Many issues remain to be resolved, including continuous
improvement in the ability of MRI to detect csPCa, specific
biomarkers for csPCa detection, and nomograms and risk
calculators to indicate patients who would benefit from
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fusion TB technique and education of urologic practitioners
are essential to enhance the utility of image-guided TB.
The main limitation of our study is a potential overopti-
mistic power calculation, leading to an underpowered study
that includedonly175patients insteadofall eligible183men
or the maximum of 192 patients required. Second, csPCa is
defined based on biopsy outcomes, not all of which were
confirmed with the gold standard of an RP specimen. Third,
only visible MRI-suspicious lesions for csPCa were targeted,
and some TBs could have failed to sample MRI-suspicious
lesions. We did not perform systematic rebiopsy in patients
with negative biopsy results or in patients included in an
active surveillance program. Thus, the true csPCa prevalence
is unknown. In addition, a limitation of our mp-MRI protocol
is omission of dynamic contrast enhancement. A further
limitation is that comparison of Gleason scores between TB
and RP specimenswas possible only for 20/86 patients (23%)
in the MRI group and 17/89 (15%) in the control group.
Finally, the cost effectiveness and potential complications of
MRI and image fusion techniques should be evaluated in a
future study.
The strengths of our study are its prospective RCT design
with inclusion of a statistically comparable population and
histologic evaluation of all prostate biopsies by the same
team of pathologists.5. Conclusion
This is the first RCT to compare MRI/TRUS-TB using
computer-assisted image fusion and conventional systemat-
icRB inbiopsy-naı¨vemen.Therewasnosignificantdifference
indetection ratesbetweentheMRIandcontrolgroups forany
PCa or csPCa. For biopsy-proven csPCas in theMRI group, 87%
were detected by MRI/TRUS-TB. csPCa detection was
comparable between two-core MRI/TRUS-TB and 12-core
RB for, and MRI/TRUS-TB detection of csPCa was further
enhanced in men with MRI-suspicious level of PIRADS 4/5.
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